首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Protective and curative effects of Bacillus subtilis SPB1 biosurfactant on high-fat-high-fructose diet induced hyperlipidemia, hypertriglyceridemia and deterioration of liver function in rats
【24h】

Protective and curative effects of Bacillus subtilis SPB1 biosurfactant on high-fat-high-fructose diet induced hyperlipidemia, hypertriglyceridemia and deterioration of liver function in rats

机译:枯草芽孢杆菌SPB1生物活性剂对高脂高果糖饮食诱导高脂血症,高甘油三酯血症及大鼠肝功能恶化的保护和疗效

获取原文
获取原文并翻译 | 示例
           

摘要

This study was aimed to assess the plausible anti-obesity effects of Bacillus subtilis SPB1 crude lipopeptide biosurfactant on high fat high fructose diet-fed rats (HFFD). Male Wistar rats were divided into five groups with the following treatment schedule: normal diet (CD), HFFD, HFFD supplemented with SPB1 biosurfactant from the first day of the experiment (HFFD + Bios1, 10 mg/kg/day), HFFD receiving standard drug (HFFD + Torva, 10 mg/kg/day) or SPB1 biosurfactant (HFFD + Bios2, 10 mg/kg/day) during the last 4 weeks of the study. The results showed an increase in body weight of HFFD by similar to 19% as compared to controls (CD). Moreover, serum lipase activity underwent a threefold increase which led to an increase in the levels of total cholesterol (T-Ch), triglycerides (TG) and LDL-cholesterol (LDL-Ch) in serum of untreated HFFD, as well as a rise in the calculated atherogenic index (AI). Furthermore, liver dysfunction indices such as AST, ALT, CPK, LDH, GGT, ALP and T-Bilirubins exhibited remarkable increases in serum of HFFD as compared to controls (CD). Whereas, the administration of Bacillus subtilis SPB1 biosurfactant to HFFD improved the body weight gain and serum lipids profile and reverted back near normal the activities of lipase and liver toxicity indicators. In addition, notable protective and curative effects were reported in liver tissues. Overall, these results suggest that the lipopeptides biosynthesized by Bacillus subtilis SPB1 achieved an anti-obesity effect through the inhibition of lipid digestive and liver dysfunction enzymes. (C) 2016 Elsevier Masson SAS. All rights reserved.
机译:本研究旨在评估枯草芽孢杆菌SPB1粗脂肽生物活性剂在高脂肪高果糖饮食喂食大鼠(HFFD)上的合理抗肥胖作用。雄性Wistar大鼠用以下治疗时间表分为五组:正常饮食(CD),HFFD,HFFD,补充有SPB1生物活性剂的来自实验的第一天(HFFD + BIOS1,10mg /天),HFFD接收标准在研究的最后4周期间,药物(HFFD + Torva,10 mg / kg /天/天)或SPB1生物活性剂(HFFD + BIOS2,11MOS2,10mg / kg /天)。结果表明,与对照(CD)相比,HFFD的体重增加到19%。此外,血清脂肪酶活性经历了三倍的增加,其导致未经治疗的HFFD的血清中总胆固醇(T-CH),甘油三酯(Tg)和Ld1-胆固醇(LDL-CH)的水平增加,以及升高在计算出的致动脉粥样格(AI)中。此外,与对照(CD)相比,肝脏功能障碍诸如AST,ALT,CPK,LDH,GGT,ALP和T-BILIRUBINS的血清表现出显着增加的HFFD。虽然,枯草芽孢杆菌SPB1生物活性剂对HFFD的给药改善了体重增加和血清脂质曲线,并在正常的脂肪酶和肝毒性指标的活动附近恢复。此外,肝脏组织中报告了显着的保护性和疗效。总的来说,这些结果表明,通过抑制脂肪消化和肝功能障碍酶,植物枯草芽孢杆菌SPB1的脂肪酸生物合成效果。 (c)2016 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号